SPC24 is critical for anaplastic thyroid cancer progression

Huabin Yin; Tong Meng; Lei Zhou; Haiyan Chen; Dianwen Song

doi:10.18632/oncotarget.15670

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

SPC24 is critical for anaplastic thyroid cancer progression

Huabin Yin, Tong Meng, Lei Zhou, Haiyan Chen and Dianwen Song _

PDF | HTML | How to cite

Oncotarget. 2017; 8:21884-21891. https://doi.org/10.18632/oncotarget.15670

Metrics: PDF 1906 views | HTML 2101 views | ?

Abstract

Huabin Yin1,*, Tong Meng1,*, Lei Zhou2,*, Haiyan Chen3, Dianwen Song1

1Department of Orthopedics, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200080, China

2Department of Bone Tumor Surgery, Changzheng Hospital, The Second Military Medical University, Shanghai, 200003, China

3Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional and Western Medicine, Shanghai, 200052, China

*These authors have contributed equally to this work

Correspondence to:

Dianwen Song, email: [email protected]

Haiyan Chen, email: [email protected]

Keywords: SPC24, metastasis, thyroid cancer

Received: December 23, 2016 Accepted: January 27, 2017 Published: February 24, 2017

ABSTRACT

In the past 2 decades, the incidence of thyroid cancer has been rapidly increasing worldwide. Anaplastic thyroid cancer (ATC) is the most lethal of all thyroid cancers and one of the most aggressive human carcinomas. SPC24 is an important component of the mitotic checkpoint machinery in the tumorigenesis and high levels of SPC24 have been found in colorectal and hepatocellular carcinomas, but its role in anaplastic thyroid cancer is still unclear. Our results showed that SPC24 was high expressed in human thyroid cancer samples. In addition, knockingdown endogenous SPC24 could repress cell growth, inhibit cell invasive ability and promote apoptosis in different ATC cells. Next, in vivo xenograft studies indicated that the SPC24 knockdown cells has decreased tumor size compared to the controls. This conclusion is also endorsed by our studies using human thyroid cancer samples. Taken together, our data demonstrates that SPC24 can serve as a promising prognostic biomarker of ATC cells and it is a novel strategy which could be developed by targeting SPC24 in future.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15670

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

SPC24 is critical for anaplastic thyroid cancer progression

Abstract